BREAST CANCER

FDA reviews gedatolisib for advanced breast cancer, showing significant progression-free survival improvements in pivotal VIKTORIA-1 trial.

Vepdegestrant emerges as a groundbreaking treatment for ESR1-mutated breast cancer, showing significant improvements in progression-free survival over traditional therapies.

A pivotal trial evaluates patritumab deruxtecan for advanced HR-positive, HER2-negative breast cancer, offering hope for patients after standard therapies.

A novel assay identifies low-risk patients with high-risk ER+/HER2– early breast cancer, potentially sparing them from unnecessary treatment escalation.

A new study reveals personalized treatment strategies for HER2-negative breast cancer, optimizing antibody-drug conjugate sequencing based on tumor characteristics.

The FDA accepts a new drug application for vepdegestrant, a promising oral PROTAC developed by Arvinas and Pfizer, signaling potential breakthroughs in treatment.

ProteinQure's PQ203, a novel peptide drug conjugate, gains FDA fast track designation for advanced triple-negative breast cancer clinical trials in North America.

A groundbreaking trial explores personalized endocrine therapy for early-stage breast cancer, aiming to reduce chemotherapy's side effects and improve patient outcomes.

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast cancer, offering hope for patients.

Atossa Therapeutics advances Z-endoxifen for ER+/HER2- metastatic breast cancer, receiving FDA support for dose optimization and combination therapy strategies.

Atezolizumab enhances long-term outcomes in triple-negative breast cancer, revealing promising insights on ctDNA as a prognostic biomarker.

A novel triple therapy shows promise for advanced triple-negative breast cancer, offering hope for patients with limited treatment options.

Mariam Eskander, MD, explores how food insecurity and geographic barriers hinder breast cancer trial participation, highlighting urgent needs for systemic change.

Patritumab deruxtecan shows promising survival rates and manageable safety in treating leptomeningeal metastatic disease, offering hope for patients with limited options.

New findings confirm that partial-breast and reduced-dose radiotherapy effectively treat low-risk early-stage breast cancer with fewer side effects.

Preliminary results from the TRIFOUR trial highlight nadunolimab's potential in treating advanced triple-negative breast cancer, showing promising efficacy and safety.

Innovative research explores targeted therapies for early triple-negative breast cancer, aiming to reduce toxicity while enhancing treatment efficacy.

A promising clinical trial shows that a combination of paxalisib, pembrolizumab, and chemotherapy significantly reduces circulating tumor cells in metastatic triple-negative breast cancer.

Sara M. Tolaney, MD, MPH, discusses new data from the ASCENT-04 trial and their implications for community oncologists.

The PALMARES-2 trial reveals that abemaciclib and ribociclib outperform palbociclib in real-world progression-free survival for advanced breast cancer patients.

Preliminary data highlights gedatolisib's potential in treating mCRPC and HER2+ mBC, showcasing promising efficacy and a favorable safety profile.

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone receptor–positive/HER2-negative breast cancer.

Discover the latest advancements in breast cancer treatment at the 24th Annual International Congress, featuring expert insights and groundbreaking research.

During a live event, Fengting Yan, MD, PhD, discussed safety outcomes from the TROPION-Breast01 and supportive care for datopotamab deruxtecan in metastatic breast cancer.